Ionis Pharmaceuticals IONS Stock
Ionis Pharmaceuticals Price Chart
Ionis Pharmaceuticals IONS Financial and Trading Overview
Ionis Pharmaceuticals stock price | 38.72 USD |
Previous Close | 40.82 USD |
Open | 40.81 USD |
Bid | 0 USD x 800 |
Ask | 0 USD x 1000 |
Day's Range | 40.6 - 41.78 USD |
52 Week Range | 32.69 - 48.82 USD |
Volume | 1.22M USD |
Avg. Volume | 1.22M USD |
Market Cap | 5.97B USD |
Beta (5Y Monthly) | 0.523591 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.67 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 48.58 USD |
IONS Valuation Measures
Enterprise Value | 4.85B USD |
Trailing P/E | N/A |
Forward P/E | -12.334319 |
PEG Ratio (5 yr expected) | 0.22 |
Price/Sales (ttm) | 10.357285 |
Price/Book (mrq) | 12.254556 |
Enterprise Value/Revenue | 8.417 |
Enterprise Value/EBITDA | -10.794 |
Trading Information
Ionis Pharmaceuticals Stock Price History
Beta (5Y Monthly) | 0.523591 |
52-Week Change | 18.23% |
S&P500 52-Week Change | 20.43% |
52 Week High | 48.82 USD |
52 Week Low | 32.69 USD |
50-Day Moving Average | 38.12 USD |
200-Day Moving Average | 39.91 USD |
IONS Share Statistics
Avg. Volume (3 month) | 1.22M USD |
Avg. Daily Volume (10-Days) | 2.1M USD |
Shares Outstanding | 143.09M |
Float | 142.04M |
Short Ratio | 5.71 |
% Held by Insiders | 0.73% |
% Held by Institutions | 93.22% |
Shares Short | 6.52M |
Short % of Float | 5.40% |
Short % of Shares Outstanding | 4.56% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -57.099% |
Operating Margin (ttm) | -80.69% |
Gross Margin | -46.34% |
EBITDA Margin | -77.98% |
Management Effectiveness
Return on Assets (ttm) | -10.75% |
Return on Equity (ttm) | -54.99% |
Income Statement
Revenue (ttm) | 575.97M USD |
Revenue Per Share (ttm) | 4.05 USD |
Quarterly Revenue Growth (yoy) | -8.00000000000000000000000000000000% |
Gross Profit (ttm) | -257866000 USD |
EBITDA | -449144000 USD |
Net Income Avi to Common (ttm) | -328880000 USD |
Diluted EPS (ttm) | -2.25 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 2.35B USD |
Total Cash Per Share (mrq) | 16.45 USD |
Total Debt (mrq) | 1.36B USD |
Total Debt/Equity (mrq) | 279.79 USD |
Current Ratio (mrq) | 9.809 |
Book Value Per Share (mrq) | 3.402 |
Cash Flow Statement
Operating Cash Flow (ttm) | -376712000 USD |
Levered Free Cash Flow (ttm) | -180147008 USD |
Profile of Ionis Pharmaceuticals
Country | United States |
State | CA |
City | Carlsbad |
Address | 2855 Gazelle Court |
ZIP | 92010 |
Phone | 760 931 9200 |
Website | https://www.ionispharma.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 796 |
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.
Q&A For Ionis Pharmaceuticals Stock
What is a current IONS stock price?
Ionis Pharmaceuticals IONS stock price today per share is 38.72 USD.
How to purchase Ionis Pharmaceuticals stock?
You can buy IONS shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Ionis Pharmaceuticals?
The stock symbol or ticker of Ionis Pharmaceuticals is IONS.
Which industry does the Ionis Pharmaceuticals company belong to?
The Ionis Pharmaceuticals industry is Biotechnology.
How many shares does Ionis Pharmaceuticals have in circulation?
The max supply of Ionis Pharmaceuticals shares is 145.96M.
What is Ionis Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Ionis Pharmaceuticals PE Ratio is now.
What was Ionis Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Ionis Pharmaceuticals EPS is -2.67 USD over the trailing 12 months.
Which sector does the Ionis Pharmaceuticals company belong to?
The Ionis Pharmaceuticals sector is Healthcare.
Ionis Pharmaceuticals IONS included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16794.88 USD — |
+0.65
|
6.83B USD — | 16695.69 USD — | 16823.83 USD — | — - | 6.83B USD — |
Dow Jones U.S. Biotechnology In DJUSBT | 2886.14 USD — |
+0.05
|
60.22M USD — | 2877.14 USD — | 2890.33 USD — | — - | 60.22M USD — |
NASDAQ Biotechnology NBI | 4468.4 USD — |
+0.8
|
— — | 4424.52 USD — | 4473.11 USD — | — - | — — |
NASDAQ HealthCare IXHC | 1001.25 USD — |
+0.4
|
— — | 995.47 USD — | 1002.74 USD — | — - | — — |
Nasdaq US Smart Pharmaceuticals NQSSPH | 1436.45 USD — |
-0.16
|
— — | 1433.84 USD — | 1439.1 USD — | — - | — — |
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2653.43 USD — |
+0.58
|
— — | 2641.29 USD — | 2657.82 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
NASDAQ Biotechnology Total Retu XNBI | 4801.39 USD — |
+0.8
|
— — | 4754.23 USD — | 4806.44 USD — | — - | — — |
NASDAQ Global Select Market Com NQGS | 8176.65 USD — |
+0.65
|
— — | 8128.16 USD — | 8191.08 USD — | — - | — — |
NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD | 2100.38 AUD 1390.15 USD |
<0.01
|
— — | 2100.38 AUD 1390.15 USD | 2100.38 AUD 1390.15 USD | — - | — — |
- {{ link.label }} {{link}}